Stockscreener 앱 받기
3.475
10.78%
0.325
전일 마감가:
$3.15
열려 있는:
$3.15
하루 거래량:
2.67M
Relative Volume:
2.34
시가총액:
$286.06M
수익:
$488.00K
순이익/손실:
$-41.44M
주가수익비율:
-3.7366
EPS:
-0.93
순현금흐름:
$-31.47M
1주 성능:
+9.05%
1개월 성능:
+2.33%
6개월 성능:
-19.59%
1년 성능:
+70.22%
1일 변동 폭
$3.07
$3.695
1주일 범위
$3.06
$3.695
52주 변동 폭
$2.01
$5.6395
Cardiff Oncology Inc Stock (CRDF) Company Profile
명칭
Cardiff Oncology Inc
전화
858-952-7570
주소
11055 FLINTKOTE AVENUE, SAN DIEGO, CA
CRDF을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CRDF
Cardiff Oncology Inc
|
3.475 | 286.06M | 488.00K | -41.44M | -31.47M | -0.93 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.37 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
538.62 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
322.94 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
547.93 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
243.32 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Cardiff Oncology Inc Stock (CRDF) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-09-06 | 개시 | Craig Hallum | Buy |
| 2022-01-05 | 개시 | William Blair | Outperform |
| 2021-12-08 | 개시 | Robert W. Baird | Outperform |
| 2021-08-09 | 재개 | Maxim Group | Buy |
| 2020-10-22 | 개시 | H.C. Wainwright | Buy |
| 2020-10-08 | 개시 | Piper Sandler | Overweight |
모두보기
Cardiff Oncology Inc 주식(CRDF)의 최신 뉴스
Cardiff Oncology (CRDF) Stock Reacts to Delayed Clinical Data Up - GuruFocus
CRDF Set to Release Key Clinical Data Amid Leadership Changes | CRDF Stock News - GuruFocus
Cardiff Oncology (CRDF) Welcomes New Chief Medical Officer | CRD - GuruFocus
Cardiff Oncology (CRDF) Shares Drop 11% After Leadership Change - GuruFocus
Cardiff Oncology appoints Dr. Roger Sidhu as Chief Medical Officer - MarketScreener
Cardiff Oncology stock falls as new medical chief named (CRDF) - Seeking Alpha
Cardiff Oncology Appoints Dr. Roger Sidhu as Chief Medical - GlobeNewswire
Cardiff Oncology Names New Chief Medical Officer - marketscreener.com
Cardiff Oncology Appoints Dr. Roger Sidhu as Chief Medical Offic - GuruFocus
Cardiff Oncology appoints Roger Sidhu as new Chief Medical Officer - Investing.com
Bank of America Corp DE Sells 11,352 Shares of Cardiff Oncology, Inc. (NASDAQ:CRDF) - Defense World
Two Sigma Investments LP Trims Stake in Cardiff Oncology, Inc. (NASDAQ:CRDF) - Defense World
Two Sigma Advisers LP Trims Stake in Cardiff Oncology, Inc. (NASDAQ:CRDF) - Defense World
ProShare Advisors LLC Acquires New Shares in Cardiff Oncology, Inc. (NASDAQ:CRDF) - Defense World
Cardiff Oncology, Inc. (CRDF) Reports 40% Response Rate in mTNBC Trial of Onvansertib + Paclitaxel - MSN
Nuveen Asset Management LLC Acquires 248,850 Shares of Cardiff Oncology, Inc. (NASDAQ:CRDF) - Defense World
Deutsche Bank AG Acquires Shares of 49,566 Cardiff Oncology, Inc. (NASDAQ:CRDF) - Defense World
Millennium Management LLC Buys 288,259 Shares of Cardiff Oncology, Inc. (NASDAQ:CRDF) - Defense World
Cardiff Oncology (CRDF) Reports Promising Phase 1b Trial Results for Breast Cancer Treatment | CRDF Stock News - GuruFocus
Cardiff Oncology Announces Positive Data From Investigator-Initiated Trial Of Onvansertib In Combination With Paclitaxel - marketscreener.com
Cardiff Oncology's Phase 1b Trial for Breast Cancer Treatment Shows 40% Objective Response Rate - marketscreener.com
Cardiff Oncology reports positive trial results for breast cancer treatment By Investing.com - Investing.com Nigeria
Cardiff Oncology reports positive trial results for breast cancer treatment - Investing.com
Cardiff Oncology Announces Positive Data from Investigator-Initi - GuruFocus
Cardiff Oncology Announces Positive Data from Investigator-Initiated Trial of Onvansertib in Combination with Paclitaxel in Metastatic Triple-Negative Breast Cancer Presented at ASCO 2025 - The Manila Times
Cardiff Oncology Reports 40% Objective Response Rate in Phase 1b Trial of Onvansertib and Paclitaxel for Metastatic Triple-Negative Breast Cancer - Nasdaq
Clinical Trial Success: Cardiff Oncology's New Drug Shows 40% Response Rate in Aggressive Breast Cancer - Stock Titan
Cardiff Oncology (CRDF) Emerges as a Prime M&A Target - GuruFocus
SA Asks: Which oncology companies are attractive M&A targets? - Seeking Alpha
Northern Trust Corp Raises Stock Holdings in Cardiff Oncology, Inc. (NASDAQ:CRDF) - Defense World
Cardiff Oncology Reports Second Quarter 2023 Results and Provides Business Update - Seeking Alpha
The Manufacturers Life Insurance Company Makes New $67,000 Investment in Cardiff Oncology, Inc. (NASDAQ:CRDF) - Defense World
Price T Rowe Associates Inc. MD Has $67,000 Stock Holdings in Cardiff Oncology, Inc. (NASDAQ:CRDF) - Defense World
13,124 Shares in Cardiff Oncology, Inc. (NASDAQ:CRDF) Bought by Voya Investment Management LLC - Defense World
Cardiff Oncology Reports Increased Losses Amid Rising R&D Costs - TipRanks
Raymond James Financial Inc. Purchases New Shares in Cardiff Oncology, Inc. (NASDAQ:CRDF) - Defense World
Cardiff Oncology (CRDF) Upgraded to Buy: Here's What You Should Know - Nasdaq
Cardiff Oncology: Buying The First-Line Onvansertib Strategy (NASDAQ:CRDF) - Seeking Alpha
Barclays PLC Purchases 9,507 Shares of Cardiff Oncology, Inc. (NASDAQ:CRDF) - Defense World
Wells Fargo & Company MN Purchases 8,851 Shares of Cardiff Oncology, Inc. (NASDAQ:CRDF) - Defense World
Cardiff Oncology First Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo
Mariner LLC Makes New $61,000 Investment in Cardiff Oncology, Inc. (NASDAQ:CRDF) - Defense World
Cardiff Oncology stock target raised to $18 by H.C. Wainwright - Investing.com Canada
Cardiff Oncology (CRDF) Gains Analyst Confidence with Price Target Increase | CRDF Stock News - GuruFocus
Cardiff Oncology (CRDF) Price Target Increased by Analyst | CRDF Stock News - GuruFocus
Cardiff Oncology: Q1 Earnings Snapshot - New Haven Register
Cardiff Oncology earnings missed by $0.01, revenue topped estimates - Investing.com Canada
Promising Clinical Trial Developments Drive Buy Rating for Cardiff Oncology - TipRanks
Cardiff Oncology (CRDF) Reports Strong Q1 Revenue and Advances Cancer Therapy | CRDF Stock News - GuruFocus
Cardiff Oncology (CRDF) Reports Q1 Loss, Lags Revenue Estimates - Yahoo Finance
Cardiff Oncology Q1 2025 Earnings: EPS Misses at -$0.20, Revenue Slightly Beats at $0.11 Million - GuruFocus
Cardiff Oncology Inc (CRDF) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Cardiff Oncology Inc 주식 (CRDF) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Levine James E. | Chief Financial Officer |
Dec 18 '24 |
Buy |
5.00 |
2,400 |
12,000 |
67,716 |
| Levine James E. | Chief Financial Officer |
Dec 16 '24 |
Buy |
3.83 |
2,564 |
9,820 |
62,564 |
| TANNENBAUM RENEE P | Director |
Dec 12 '24 |
Buy |
3.42 |
10,000 |
34,224 |
20,000 |
| PACE GARY W | Director |
Dec 11 '24 |
Buy |
2.60 |
350,115 |
910,299 |
1,047,876 |
| PACE GARY W | Director |
Dec 11 '24 |
Buy |
2.60 |
11,500 |
29,900 |
1,059,376 |
0.61%
0.56%
자본화:
|
볼륨(24시간):